Skip to main content
PPN WorldPPN World

PPN World · Archive

Reserved for subscribers

This release sits in the PPN World archive. Subscribers read the full wire as it lands — 80+ newswires, 190+ countries, searchable back through the archive, with alerts on the subjects they track.

  • Every release, the moment it crosses — not a daily digest
  • Search and filter the full archive, not the last 24 hours
  • Instant alerts on saved searches

PPN World — real-time press release intelligence.

New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis · Eli Lilly — News Releases · PPN World